| Characteristic | n | Percentage |
|---|
| Age |
| ≥ 50 | 30 | 73% |
| < 50 | 11 | 27% |
| Sex |
| Female | 25 | 61% |
| Male | 16 | 39% |
| Primary tumor site a |
| Ovary | 9 | 22% |
| Breast | 4 | 10% |
| Colon | 3 | 7% |
| Soft tissues | 3 | 7% |
| Brain | 3 | 7% |
| Lymphatic system | 3 | 7% |
| Lung | 2 | 5% |
| Kidney | 2 | 5% |
| Uterus | 2 | 5% |
| Rectum | 2 | 5% |
| Others | 8 | 20% |
| Metastases b |
| With metastatic disease | 27 | 66% |
| Without metastases | 14 | 34% |
| Metastatic sites c |
| Lung | 10 | 26% |
| Lymph nodes | 7 | 18% |
| Peritoneum | 5 | 13% |
| Liver | 5 | 13% |
| Bone | 4 | 10% |
| Brain | 3 | 8% |
| Ovary | 2 | 5% |
| Others | 3 | 8% |
- Patients diagnosed with solid tumors or hematologic malignancies were included in the CUP after completing all steps of the recruiting process. aat the time of initial diagnosis; b metastases at the time of enrollment; c metastatic sites found in 27 patients with metastatic disease
